Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Pigment Cell & Melanoma Research|July 5, 2014
Protein signatures correspond to survival outcomes of AJCC stage III melanoma patientsSwetlana Mactier, Kimberley L Kaufman, Penghao Wang, et al.
Molecular Cancer Therapeutics|May 7, 2013
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanomaMatteo S Carlino, Kavitha Gowrishankar, Catherine A B Saunders, et al.
The Journal of Investigative Dermatology|June 7, 2014
The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cellsStuart J Gallagher, Branka Mijatov, Dilini Gunatilake, et al.
Cell|May 19, 2010
IGFBP7 is not required for B-RAF-induced melanocyte senescenceLyndee L Scurr, Gulietta M Pupo, Therese M Becker, et al.
Biomarker Research|May 16, 2017
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicingGulietta M Pupo, Suzanah C Boyd, Carina Fung, et al.
NPJ Digital Medicine|July 5, 2022
Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicineKevin Y X Wang, Gulietta M Pupo, Varsha Tembe, et al.
The Journal of Investigative Dermatology|November 30, 2012
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasionSuzanah C Boyd, Branka Mijatov, Gulietta M Pupo, et al.
Pathology|March 30, 2016
Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision makingRicardo De Paoli-Iseppi, Peter A Johansson, Alexander M Menzies, et al.
Cancer Discovery|May 17, 2012
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitorsHubing Shi, Gatien Moriceau, Xiangju Kong, et al.
Molecular Cancer Therapeutics|March 3, 2012
A high-throughput panel for identifying clinically relevant mutation profiles in melanomaKen Dutton-Regester, Darryl Irwin, Priscilla Hunt, et al.
Pageof 7